UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2019
Commission File Number
001-37846

CELLECT BIOTECHNOLOGY LTD.

(Translation of registrant's name into English)

23 Hata'as Street
Kfar Saba, Israel 44425
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

Cellect Biotechnology Ltd. has posted to its website an updated corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 and is incorporated herein by reference.

Exhibit

99.1	Corporate Presentation dated May 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Cellect Biotechnology Ltd.

By: /s/ Eyal Leibovitz
Name: Eyal Leibovitz
Title: Chief Financial Officer

Date: April 30, 2019

Exhibit 99.1

FORWARD LOOKING STATEMENTS

This presentation includes statements that are, or may be deemed, "forward-looking statements." In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," potential" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. For example, forward-looking statements are used in this presentation when we discuss the potential for the Company's technology to be used for various indications and applications, the potential advantages of the Company's technology over its competitors, and our future plans which may include licensing. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements could differ materially from those described in or implied by the statements in this presentation. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of Fasl; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation as a result of, among other factors, the factors referenced in the "Risk Factors" section of contained in our most recent Annual Report on Form 20-F filed with the SEC (the "Annual Report").

In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be predictive of results or developments in future periods. Any forward-looking statement that we make in this presentation speaks only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Annual Report and in the Company's period filings with the SEC.

TABLE OF CONTENT

NEXT IN MEDICINE

Replacing tissues and organs instead of fixing them



REGENERATIVE MEDICINE CAN REVOLUTIONIZE TREATMENTS OF

DIABETES
ORTHOPEDIC TISSUE REPAIR
SPINAL CORD DAMAGE
HEART DISEASE
LIVER DISEASE
CANCER

AND MANY MORE

IMMEDIATE MARKET

Hundreds of regenerative medicine products under FDA approval route



PHARMA COMPANIES - NOVARTIS, GILEAD
RESEARCH CENTERS - HARVARD
CLINICAL TRIALS - WASHINGTON UNIVERSITY

FDA 2019

Recent FDA news puts Cell Therapy companies in the forefront

- "... The FDA plans to hire at least 50 new clinical reviewers tasked with assessing **cell and gene therapies** to prepare for what the agency describes as a **surge of cutting-edge products**...
- ... the agency expects to receive at least **200 new drug (IND) applications annually**... The FDA predicts those will translate into **10 to 20 cell and gene therapy approvals each year** by 2025...
- Those 200 annual IND applications will build upon the more than **800 active cell-based therapies** that the agency currently has on file..."

FDA COMMISSIONER SCOTT GOTTLIEB, M.D.,
AND CBER DIRECTOR PETER MARKS, M.D., PH.D

THE WAY

Use stem cells as raw material for ‘replacement parts’



THE NEED

$15.63 B **stem cells market** by 2025* supporting global regenerative medicine development

Hundreds of treatments under FDA route requiring substantial funds for safe, enriched and high-quality stem cells

*GRANDVIEW RESEARCH 2019

THE CHALLENGE

Current methods of stem cells production do not deliver

NON-STANDARD
TIME CONSUMING
EXTREMELY EXPENSIVE
TOXIC

THE SOLUTION - CELLECT

The **only** current solution intended for safe, mass production and supply of enriched, high-quality stem cells



FIRST PRODUCT – APOTAINER™

Para-magnetic micro-beads-based system coated with human protein that specifically eliminates the harming cells out of a cells mass

Value proposition

SAFE

FAST

AFFORDABLE

SECOND PRODUCT – FAT STEM CELLS

Proprietary matrix - coated with human protein that naturally enhances the stem cells expansion in quality and quantity



Value proposition

SAFE

FAST

AFFORDABLE

THE DIFFERENTIATION



CURRENT SOLUTIONS

EXPENSIVE
TAKES WEEKS
TOXIC
NOT SCALABLE



CELLECT'S VALUE PROPOSITION

COST-EFFECTIVE
FAST
SAFE
SCALABLE

WHY NOW

Convergence point



BUSINESS MODEL

Out licensing with upfront fees + royalties

879 LICENSING DEALS IN LIFE SCIENCES SECTOR, Q1/2018; DISCLOSED VALUE OF ~$35.2B

ENTEROME, GLOBAL LISENCING AND CO-DEVELOPMENT WITH TAKEDA; $50M UPFRONT + $640M IN MILESTONES

STRONG IP PORTFOLIO

65 patents owned by the Company with 32 already approved

USING APOPTOSIS-INDUCING AGENTS FOR STEM CELLS SELECTION - **GRANTED**
COMPOSITION OF MATTER OF APOTAINERS™- **GRANTED**
METHODS OF USE - **GRANTED**
METHOD OF MANUFACTURING APOTAINERS™ - **GRANTED**
MESENCHYMAL STEM CELLS SELECTION
EXPIRATION OF CONCEPT PATENT - **2029**

STRONG IP VALIDATED BY PROOF-OF-CONCEPT STUDIES

TIMELINE

Business development in process with expected first licensing & royalties deals within 18 months

SALES TO PHARMA COMPANIES ARE EXPECTED TO NOT REQUIRE **FDA** APPROVAL BEYOND SAFETY

TEAM

ADVISORY BOARD

Prof. SUSAN ALPERT
Ex FDA

Prof. COREY CUTLER
Harvard Medical School

Prof. JOHN F. DiPERSIO
Washington University

Prof. DOV ZIPORI
Weizmann Institute of Science

Prof. ROBERT S. NEGRIN
Stanford University

BOARD

Dr. MICHAEL BERELOWITZ
Ex Pfizer

DAVID BRAUN
Merck

ABRAHAM NAHMIAS
C.P.A, B.A

JONATHAN BURGIN
A NASDAQ Company CFO

Mrs. RUHAMA ABRAHAM
Ex Deputy Knesset Speaker

MANAGEMENT

Dr. Shai Yarkoni
Co-Founder & CEO

Nuriel Chirich Kasbian
Co-Founder & Executive Chairman

Eyal Leibovitz
CFO

Dr. Ronit Bakimer-Kleiner
Chief Development Officer

Amos Ofer
VP Operations

YAEL KENAN
VP Clinical Affairs

2

NEXT


CELLECT
Thank you

RESULTS

- Strong Pre-Clinical Data
- Multiple animal models (i.e. cancer, Diabetes (T1), orthopedics and transplantation)
- >200 human bone marrow donor samples tested
- Human clinical trial – half study population recruited – mid study results published